Black checkmark with a sparkle and a curved line underneath on a white background.
Company

ALX ONCOLOGY HOLDINGS INC

Ticker
ALXO
Sector
Industry
Report date
November 16, 2026
Valye AI Score

96

Very high visibility
Recent developments
Recent developments summary

Recent developments for ALX Oncology include earnings transcripts and call highlights for Q1 2026, presentations of clinical data for evorpacept, and capital raising activities including a $150 million offering of shares and pre-funded warrants. Market commentary has discussed the company’s stock performance relative to medical peers.

Recent developments:
  • ALX Oncology released its Q1 2026 earnings transcript detailing financial results and operational updates [N2].
  • The company held a Q1 earnings call highlighting clinical progress and financial status [N3].
  • ALX Oncology presented Phase 2 data of evorpacept in frontline indolent non-Hodgkin lymphoma at the ASH conference [N1].
  • The company announced pricing of a $150 million offering of shares and pre-funded warrants to support ongoing operations [N1].
  • Market analysis articles have discussed ALX Oncology’s stock performance relative to other medical and biotech peers this year [N1].
Overview

ALX Oncology Holdings Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cancer therapies. The company’s lead product candidates, evorpacept (ALX 148) and ALX2004, are in early clinical development stages, including Phase 1 and Phase 2 trials. ALX Oncology has no approved products or commercial revenue and has historically financed operations through equity offerings and private placements. The company’s financial position as of September 30, 2026, shows substantial liquidity with cash and investments totaling approximately $147.2 million and a strong current ratio of 8.04. ALX Oncology has a secured loan facility with HSBC Ventures USA Inc. that includes customary covenants and restrictions. The company’s business model centers on advancing clinical trials, obtaining regulatory approvals, establishing manufacturing and commercialization capabilities, and managing intellectual property. Risks include clinical trial outcomes, regulatory uncertainties, capital requirements, and market acceptance.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. ALX Oncology Holdings Inc is a clinical-stage biopharmaceutical company focused on oncology drug development with no approved products or revenue to date. The company reported a net loss of $21.8 million for Q3 2026 and held $147.2 million in cash, cash equivalents, and short-term investments as of September 30, 2026, supporting liquidity ratios above 7.7. ALX Oncology’s operations depend on advancing clinical trials of its lead candidates evorpacept and ALX2004, managing regulatory and development risks, and securing additional capital as needed. The company has a secured loan facility with HSBC Ventures USA Inc. with covenants that may restrict operational flexibility. Recent news coverage includes earnings transcripts, clinical data presentations, and capital raising activities, reflecting ongoing development and market interest.

Scenarios for ALXO

Bull case model:

The company’s lead candidates, evorpacept and ALX2004, have advanced into early clinical trials, demonstrating progress in oncology drug development. ALX Oncology maintains a strong liquidity position with over $147 million in cash and investments as of September 2026, supporting ongoing research and development activities. The secured loan facility with HSBC provides additional capital flexibility. Recent news coverage highlights active clinical data presentations and capital raising efforts, indicating operational momentum and investor interest.

Bear case model:

ALX Oncology has incurred significant net losses since inception and continues to operate without commercial products or revenue, relying on capital markets and debt financing to fund operations. The company faces risks typical of early-stage biopharmaceutical firms, including clinical trial failures, regulatory delays, and the need for substantial additional capital. Covenants in the secured loan facility may restrict operational flexibility and pose risks if financial or operational targets are not met. Market volatility and competitive pressures in the oncology sector add to the uncertainty of future success.

Moat:

ALX Oncology’s moat is primarily based on its proprietary oncology drug candidates in clinical development, including evorpacept and ALX2004, and its intellectual property portfolio. As a clinical-stage biopharmaceutical company, its competitive advantage depends on successful clinical trial results, regulatory approvals, and the ability to protect its innovations through patents and trade secrets. The company’s early-stage status and lack of commercial products mean its moat is contingent on future development milestones and market acceptance, which are subject to significant risks and uncertainties.

Risks overview
Risks summary
The most significant risks for ALX Oncology relate to clinical development uncertainties, capital needs, regulatory approval challenges, and financial covenant restrictions that could impact operational flexibility and funding availability.
Risks details:

• Clinical Development Risk: The success of ALX Oncology depends on the successful and timely completion of clinical trials for its product candidates, which are in early stages. Failure to demonstrate safety and efficacy could materially harm the business.
• Capital Requirements and Financing Risk: The company requires substantial additional capital to fund operations and clinical development. Inability to raise capital on acceptable terms could force delays or reductions in research and development programs.
• Regulatory Risk: Regulatory approval processes are lengthy, unpredictable, and may require additional studies or data, potentially delaying or preventing commercialization.
• Operational and Financial Covenants Risk: The secured loan facility with HSBC includes covenants that restrict operational flexibility and could lead to default and acceleration of repayment obligations, adversely impacting the company.
• Market and Competitive Risk: ALX Oncology operates in a competitive oncology market with evolving technologies and therapies. Market acceptance and reimbursement challenges could affect commercial viability.

FINAL FORECAST FOR ALXO

Final take one line
ALX Oncology is a clinical-stage biopharmaceutical company with detailed disclosures and active clinical and capital development efforts, facing typical early-stage biotech risks.
Final take 12 to 24 month view

Business trends: Continued clinical development of lead candidates evorpacept and ALX2004 with active capital raising to support operations.
Execution milestones: Completion of ongoing clinical trials, regulatory submissions, and potential achievement of development milestones tied to loan facility draws.
Key risks: Clinical trial outcomes, regulatory approval uncertainties, capital availability, and financial covenant compliance risks.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

96
LLM visibility overview
LLM Visibility known facts
  • ALX Oncology Holdings Inc is a clinical-stage biopharmaceutical company focused on developing cancer therapies, with lead product candidates evorpacept (ALX 148) and ALX2004 in early-stage clinical trials.
  • The company has no products approved for commercial sale and has not generated revenue from product sales, licenses, or collaborations to date.
  • ALX Oncology has incurred significant net losses since inception and continues to incur losses; net loss was $21.8 million for the three months ended September 30, 2026, and $57.7 million for the nine months ended September 30, 2026.
  • As of September 30, 2026, ALX Oncology had cash, cash equivalents, and short-term investments totaling approximately $147.2 million.
  • The company’s current ratio as of September 30, 2026, was 8.04, indicating strong liquidity relative to current liabilities of $19.0 million.
  • ALX Oncology entered into a secured multi-tranche term loan facility with HSBC Ventures USA Inc. for up to $50 million, with $10 million drawn as of June 2026 and potential additional draws subject to milestones and lender discretion.
  • The loan agreement contains customary covenants and restrictions that could limit operational flexibility and includes events of default that could accelerate repayment obligations.
  • The company’s business depends heavily on successful clinical development, regulatory approval, manufacturing, and commercialization of its product candidates, which remain in early clinical stages.
  • ALX Oncology’s ability to generate revenue and achieve profitability depends on multiple factors including successful clinical trials, regulatory approvals, manufacturing scale-up, market acceptance, and intellectual property protection.
  • The company faces risks typical of early-stage biopharmaceutical firms, including clinical trial failures, regulatory delays, capital needs, and market volatility.
  • Recent news highlights include Q1 2026 earnings transcripts and call highlights, clinical data presentations, and capital raising activities such as a $150 million offering of shares and pre-funded warrants.
  • ALX Oncology’s stock performance and peer comparisons have been discussed in recent Nasdaq articles, reflecting market interest and volatility in the medical and biotech sectors.
Sources
Sources - Context summary

Generated 2026-11-16

Sources - Earning calls
  • N3
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-09 | 10-K
  • S2 | 2026-11-16 | 10-Q
Sources - News headlines
  • N1 | 2026-08-11 | www.nasdaq.com | Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year? | https://www.nasdaq.com/articles/alx-oncology-holdings-alxo-stock-outpacing-its-medical-peers-year
  • N2 | 2026-06-01 | www.nasdaq.com | ALX Oncology (ALXO) Q1 2026 Earnings Transcript | https://www.nasdaq.com/articles/alx-oncology-alxo-q1-2026-earnings-transcript
  • N3 | 2026-05-08 | www.nasdaq.com | ALX Oncology Q1 Earnings Call Highlights | https://www.nasdaq.com/articles/alx-oncology-q1-earnings-call-highlights
  • N4 | 2026-03-13 | www.nasdaq.com | Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4 | https://www.nasdaq.com/articles/allogene-therapeutics-posts-narrower-expected-loss-q4
  • N5 | 2026-03-13 | www.nasdaq.com | Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? | https://www.nasdaq.com/articles/adc-therapeutics-adct-outperforming-other-medical-stocks-year
  • N6 | 2026-03-06 | www.nasdaq.com | Mirum Completes Enrollment & Screening in Liver Disease Studies | https://www.nasdaq.com/articles/mirum-completes-enrollment-screening-liver-disease-studies
  • N7 | 2026-03-05 | www.nasdaq.com | ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised) | https://www.nasdaq.com/articles/acad-plans-re-examination-after-chmp-rejects-rett-syndrome-drug-eu-revised
  • N8 | 2026-03-04 | www.nasdaq.com | ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU | https://www.nasdaq.com/articles/acad-plans-re-examination-after-chmp-rejects-rett-syndrome-drug-eu
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine